<DOC>
	<DOC>NCT01185522</DOC>
	<brief_summary>This prospective, observational study will assess the effect of RoActemra/Actemra (tocilizumab) on fatigue in patients with moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARDS) or anti tumor necrosis factor (anti-TNF) drugs. Eligible patients receiving RoActemra/Actemra according to the standard of care will be followed for 4 months.</brief_summary>
	<brief_title>An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis Inadequate response to diseasemodifying antirheumatic drugs (DMARDS) or antiTNF (tumor necrosis factor) drugs Hypersensitivity to RoActemra/Actemra or any component Active infection Participation in a clinical trial in rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>